Mark Cuban’s “Cost-Plus Drugs” pitch was supposed to fix a broken system. But the loudest takeaway from the latest DrugPatentWatch analysis is this: the way we talk about “spread pricing” may be doing more harm than good—because it can obscure what’s a…

Generic vs. brand: why “cost-plus” can’t be a one-size-fits-all solution
The promise of cost-plus drug pricing is simple: cut out the markup games, tie prices to something closer to reality, and let competition do the rest. For generics, that model has…

Drug pricing is a black box—until you look at the math.
Most people think drug prices are set by “market forces.” But if you’ve ever wondered why the same medication can cost wildly different amounts depending on where you live—or why certain price mov…

Mark Cuban’s generic-drug play isn’t just another healthcare headline—it’s a stress test for the entire economics of “protected” medicine.
For years, the industry’s default story has been simple: innovation is expensive, patents create certainty, and e…

Biotech hiring is often treated like a lagging indicator—something that happens after the science is already funded, the pipeline is already de-risked, and the next clinical milestone is already “in motion.”
But in 2026, that assumption is getting risk…

Patent cliffs aren’t just a legal event. They’re a pricing strategy.
If you’ve worked anywhere near pharma—commercial, finance, strategy, or policy—you’ve seen the pattern: a blockbuster’s exclusivity ends, generic competition arrives, and revenue cu…

Drug pricing transparency is having a moment. In boardrooms and policy circles, the idea sounds almost surgical: publish the numbers, expose the math, and let sunlight do what regulation can’t. But the argument that “more transparency is always better”…

Mark Cuban’s Cost-Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
The healthcare market is entering a phase that looks less like “policy debate” and more like competitive strategy—with winners and losers determined by pri…

Pharma doesn’t just “manage patents.” It manages time.
In the race for global exclusivity, the real asset isn’t only the molecule—it’s the calendar. And behind the scenes, companies are building systems to track IND and NDA milestones with near-obsessi…

Pharma doesn’t just “watch” patent dates. It engineers outcomes around them.
In the race to secure global exclusivity, the real advantage isn’t only having the best science—it’s having the best calendar. Drug Patent Watch’s latest piece on how companie…